Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Prostatic Neoplasms 16Breast Neoplasms 10Brain Neoplasms 7Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma 4Urinary Bladder Neoplasms 3Spinal Cord Neoplasms 3Multiple Myeloma 2Lymphoma, B-Cell 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Vasculitis 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocythemia, Essential 1Thoracic Neoplasms 1Thoracic Diseases 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinal Diseases 1Solid Tumor, Adult 1Sinusitis 1Sarcoma 1

Interventions

Cyclophosphamide 125Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 81Etoposide 73Filgrastim 64Mycophenolic Acid 63Tacrolimus 57Whole-Body Irradiation 55Busulfan 52Doxorubicin 50Radiotherapy 48Melphalan 48Cyclosporine 47Brentuximab Vedotin 45Rituximab 39Vinblastine 37fludarabine 36Granulocyte Colony-Stimulating Factor 36Antilymphocyte Serum 35Prednisone 33Methotrexate 32Vincristine 31Gemcitabine 30Dacarbazine 29Bleomycin 29Cytarabine 26Carmustine 22Bendamustine Hydrochloride 21Sirolimus 18Ifosfamide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hodgkin Disease × Magnetic Resonance Imaging × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡